Germany: Evotec raises US$435m from ADS offering on Nasdaq

Evotec, a drug discovery and development company headquartered in Hamburg, Germany, has raised US$435m from a Nasdaq cross-listing. The deal was downsized from an initially envisaged US$576m. The public offering of American Depositary Shares (ADS) consisted of 20 million ADS (downsized from 22 million), priced at US$21.75 per ADS, representing 10 million ordinary shares of…

You must be a HMI Subscriber to view this content.

Subscribe Now »